New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:17 EDTMDTMedtronic's SYMPLICITY HTN-3 trial fails to meet primary efficacy endpoint
Medtronic announced that its U.S. pivotal trial in renal denervation for treatment-resistant hypertension, SYMPLICITY HTN-3, failed to meet its primary efficacy endpoint. The trial met its primary safety endpoint, and the trial's Data Safety Monitoring Board concluded that there were no safety concerns in the study. Based on these clinical trial findings, Medtronic intends to formulate a panel of independent advisors made up of physicians and researchers who will be asked to make recommendations about the future of the global hypertension clinical trial program, as well as provide advice on continued physician and patient access to the Symplicity technology in countries with regulatory approvals.
News For MDT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
09:02 EDTMDTMedtronic announces Irish High Court approval of share premium reduction
Subscribe for More Information
February 24, 2015
13:02 EDTMDTMedtronic confirms FDA approval of VenaSeal closure system
Subscribe for More Information
February 23, 2015
08:40 EDTMDTMedtronic acquires Advanced Uro-Solutions, terms not disclosed
Medtronic announced that it has acquired Advanced Uro-Solutions, a privately-held developer of neurostimulation products for the treatment of bladder control issues based in Elizabethton, Tennessee. Terms of the acquisition agreement, which closed in December 2014, were not disclosed.
February 20, 2015
12:19 EDTMDTFDA approves closure system to permanently treat varicose veins
Subscribe for More Information
February 19, 2015
16:15 EDTMDTMedtronic SANTE trial data show sustained safety, improvements in QOLIE-31
Subscribe for More Information
February 17, 2015
09:29 EDTMDTMedtronic says FY16 constant currency revenue may be up mid-single digit range
Subscribe for More Information
09:27 EDTMDTMedtronic, Covidien targeting over $850M in cost synergies through FY18
Subscribe for More Information
08:49 EDTMDTMedtronic sees being at high end of Q4 revenue growth range
Subscribe for More Information
07:19 EDTMDTMedtronic sees Q4 revenue up 4%-6%
Subscribe for More Information
07:18 EDTMDTMedtronic reports Q3 EPS $1.01, consensus 97c
Subscribe for More Information
February 16, 2015
13:59 EDTMDTMedtronic receives expanded indications of the Vertex Reconstruction System
Subscribe for More Information
12:30 EDTMDTMedtronic announces CE mark, European launch of the Euphora catheter
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use